Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .
The involvement of the PD1/PDL1 pathway in cancer-tumour cross-talk and tumour escape is not something new. This pathway is deeply screened in Drug discovery programs and particularly in Immunotherapy (ie. treatments of diseases that induce, enhance, or surpress an immune response) together with other therapeutical promising pathways (IDO, CD137:CD137L, CD40:CD40L, OX40:OX40L, GITR:GITRL, BLTA:HVEM, CD47:SIRPa, B7-1 / CD28 and B7-1 / CTLA4).
In a recent publication, researchers from the University of Texas investigated the mechanisms governing this pathway.